nodes	percent_of_prediction	percent_of_DWPC	metapath
Loperamide—CYP2B6—Efavirenz—acquired immunodeficiency syndrome	0.0405	0.06	CbGbCtD
Loperamide—CYP2B6—Nevirapine—acquired immunodeficiency syndrome	0.0381	0.0564	CbGbCtD
Loperamide—CYP2B6—Lopinavir—acquired immunodeficiency syndrome	0.0381	0.0564	CbGbCtD
Loperamide—CYP2B6—Amprenavir—acquired immunodeficiency syndrome	0.0344	0.051	CbGbCtD
Loperamide—CYP2B6—Nelfinavir—acquired immunodeficiency syndrome	0.0289	0.0427	CbGbCtD
Loperamide—CYP2B6—Ritonavir—acquired immunodeficiency syndrome	0.0261	0.0386	CbGbCtD
Loperamide—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0261	0.0386	CbGbCtD
Loperamide—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0261	0.0386	CbGbCtD
Loperamide—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0198	0.0293	CbGbCtD
Loperamide—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0198	0.0293	CbGbCtD
Loperamide—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0196	0.029	CbGbCtD
Loperamide—ABCB1—Lopinavir—acquired immunodeficiency syndrome	0.0195	0.0289	CbGbCtD
Loperamide—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.019	0.0281	CbGbCtD
Loperamide—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0184	0.0272	CbGbCtD
Loperamide—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0184	0.0272	CbGbCtD
Loperamide—ABCB1—Amprenavir—acquired immunodeficiency syndrome	0.0177	0.0261	CbGbCtD
Loperamide—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0166	0.0246	CbGbCtD
Loperamide—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0166	0.0246	CbGbCtD
Loperamide—ABCB1—Indinavir—acquired immunodeficiency syndrome	0.0152	0.0226	CbGbCtD
Loperamide—ABCB1—Nelfinavir—acquired immunodeficiency syndrome	0.0148	0.0219	CbGbCtD
Loperamide—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0144	0.0213	CbGbCtD
Loperamide—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0139	0.0206	CbGbCtD
Loperamide—ABCB1—Saquinavir—acquired immunodeficiency syndrome	0.0134	0.0198	CbGbCtD
Loperamide—ABCB1—Ritonavir—acquired immunodeficiency syndrome	0.0134	0.0198	CbGbCtD
Loperamide—ABCB1—Zidovudine—acquired immunodeficiency syndrome	0.0128	0.019	CbGbCtD
Loperamide—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0126	0.0187	CbGbCtD
Loperamide—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0126	0.0187	CbGbCtD
Loperamide—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0124	0.0184	CbGbCtD
Loperamide—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0117	0.0173	CbGbCtD
Loperamide—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0117	0.0173	CbGbCtD
Loperamide—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0106	0.0157	CbGbCtD
Loperamide—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0106	0.0157	CbGbCtD
Loperamide—ABCB1—Lamivudine—acquired immunodeficiency syndrome	0.00992	0.0147	CbGbCtD
Loperamide—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.00913	0.0135	CbGbCtD
Loperamide—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.00887	0.0131	CbGbCtD
Loperamide—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.00802	0.0119	CbGbCtD
Loperamide—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.00802	0.0119	CbGbCtD
Loperamide—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.00769	0.0114	CbGbCtD
Loperamide—POMC—nerve—acquired immunodeficiency syndrome	0.00612	0.0691	CbGeAlD
Loperamide—CACNA1A—nerve—acquired immunodeficiency syndrome	0.00585	0.066	CbGeAlD
Loperamide—POMC—blood plasma—acquired immunodeficiency syndrome	0.00463	0.0523	CbGeAlD
Loperamide—CALM2—semen—acquired immunodeficiency syndrome	0.00347	0.0392	CbGeAlD
Loperamide—CALM1—semen—acquired immunodeficiency syndrome	0.00345	0.039	CbGeAlD
Loperamide—OPRM1—nerve—acquired immunodeficiency syndrome	0.0023	0.026	CbGeAlD
Loperamide—POMC—skin of body—acquired immunodeficiency syndrome	0.00223	0.0251	CbGeAlD
Loperamide—POMC—lymphoid tissue—acquired immunodeficiency syndrome	0.0018	0.0203	CbGeAlD
Loperamide—POMC—digestive system—acquired immunodeficiency syndrome	0.00178	0.0201	CbGeAlD
Loperamide—POMC—blood—acquired immunodeficiency syndrome	0.0017	0.0191	CbGeAlD
Loperamide—CALM2—nerve—acquired immunodeficiency syndrome	0.00167	0.0189	CbGeAlD
Loperamide—CALM1—nerve—acquired immunodeficiency syndrome	0.00166	0.0188	CbGeAlD
Loperamide—POMC—spinal cord—acquired immunodeficiency syndrome	0.00163	0.0184	CbGeAlD
Loperamide—POMC—vagina—acquired immunodeficiency syndrome	0.00157	0.0177	CbGeAlD
Loperamide—POMC—lung—acquired immunodeficiency syndrome	0.00149	0.0168	CbGeAlD
Loperamide—CALM2—endothelium—acquired immunodeficiency syndrome	0.00142	0.0161	CbGeAlD
Loperamide—CALM1—endothelium—acquired immunodeficiency syndrome	0.00142	0.016	CbGeAlD
Loperamide—POMC—nervous system—acquired immunodeficiency syndrome	0.00138	0.0155	CbGeAlD
Loperamide—POMC—central nervous system—acquired immunodeficiency syndrome	0.00133	0.015	CbGeAlD
Loperamide—CACNA1A—nervous system—acquired immunodeficiency syndrome	0.00131	0.0148	CbGeAlD
Loperamide—CACNA1A—central nervous system—acquired immunodeficiency syndrome	0.00127	0.0143	CbGeAlD
Loperamide—CALM2—blood plasma—acquired immunodeficiency syndrome	0.00126	0.0143	CbGeAlD
Loperamide—CALM1—blood plasma—acquired immunodeficiency syndrome	0.00126	0.0142	CbGeAlD
Loperamide—POMC—brain—acquired immunodeficiency syndrome	0.00105	0.0119	CbGeAlD
Loperamide—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.00105	0.0118	CbGeAlD
Loperamide—CACNA1A—brain—acquired immunodeficiency syndrome	0.001	0.0113	CbGeAlD
Loperamide—CYP2B6—blood plasma—acquired immunodeficiency syndrome	0.00094	0.0106	CbGeAlD
Loperamide—CALM3—retina—acquired immunodeficiency syndrome	0.000882	0.00995	CbGeAlD
Loperamide—OPRD1—nervous system—acquired immunodeficiency syndrome	0.00076	0.00858	CbGeAlD
Loperamide—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.000732	0.00826	CbGeAlD
Loperamide—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000729	0.00822	CbGeAlD
Loperamide—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00071	0.00801	CbGeAlD
Loperamide—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000701	0.00792	CbGeAlD
Loperamide—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000699	0.00789	CbGeAlD
Loperamide—CALM2—retina—acquired immunodeficiency syndrome	0.000693	0.00782	CbGeAlD
Loperamide—CALM1—retina—acquired immunodeficiency syndrome	0.000689	0.00778	CbGeAlD
Loperamide—OPRM1—blood—acquired immunodeficiency syndrome	0.000638	0.00721	CbGeAlD
Loperamide—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000615	0.00694	CbGeAlD
Loperamide—CALM2—skin of body—acquired immunodeficiency syndrome	0.000608	0.00686	CbGeAlD
Loperamide—CALM1—skin of body—acquired immunodeficiency syndrome	0.000605	0.00683	CbGeAlD
Loperamide—CALM3—blood—acquired immunodeficiency syndrome	0.00059	0.00666	CbGeAlD
Loperamide—OPRD1—brain—acquired immunodeficiency syndrome	0.000581	0.00656	CbGeAlD
Loperamide—CALM3—bone marrow—acquired immunodeficiency syndrome	0.000571	0.00644	CbGeAlD
Loperamide—CALM3—spinal cord—acquired immunodeficiency syndrome	0.000568	0.00642	CbGeAlD
Loperamide—OPRK1—brain—acquired immunodeficiency syndrome	0.000557	0.00628	CbGeAlD
Loperamide—CALM3—vagina—acquired immunodeficiency syndrome	0.000547	0.00617	CbGeAlD
Loperamide—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000518	0.00585	CbGeAlD
Loperamide—CALM3—lung—acquired immunodeficiency syndrome	0.000517	0.00584	CbGeAlD
Loperamide—ABCB1—blood plasma—acquired immunodeficiency syndrome	0.000503	0.00567	CbGeAlD
Loperamide—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000499	0.00563	CbGeAlD
Loperamide—CALM2—lymphoid tissue—acquired immunodeficiency syndrome	0.000492	0.00556	CbGeAlD
Loperamide—CALM1—lymphoid tissue—acquired immunodeficiency syndrome	0.00049	0.00553	CbGeAlD
Loperamide—CALM2—digestive system—acquired immunodeficiency syndrome	0.000486	0.00549	CbGeAlD
Loperamide—CALM1—digestive system—acquired immunodeficiency syndrome	0.000484	0.00546	CbGeAlD
Loperamide—CALM2—blood—acquired immunodeficiency syndrome	0.000463	0.00523	CbGeAlD
Loperamide—CALM1—blood—acquired immunodeficiency syndrome	0.000461	0.00521	CbGeAlD
Loperamide—CYP2B6—skin of body—acquired immunodeficiency syndrome	0.000452	0.0051	CbGeAlD
Loperamide—CALM2—bone marrow—acquired immunodeficiency syndrome	0.000448	0.00506	CbGeAlD
Loperamide—CALM2—spinal cord—acquired immunodeficiency syndrome	0.000446	0.00504	CbGeAlD
Loperamide—CALM1—bone marrow—acquired immunodeficiency syndrome	0.000446	0.00504	CbGeAlD
Loperamide—CALM1—spinal cord—acquired immunodeficiency syndrome	0.000444	0.00501	CbGeAlD
Loperamide—CALM2—vagina—acquired immunodeficiency syndrome	0.00043	0.00485	CbGeAlD
Loperamide—CALM1—vagina—acquired immunodeficiency syndrome	0.000428	0.00482	CbGeAlD
Loperamide—Dyspepsia—Nelfinavir—acquired immunodeficiency syndrome	0.000412	0.00259	CcSEcCtD
Loperamide—Flatulence—Delavirdine—acquired immunodeficiency syndrome	0.000412	0.00259	CcSEcCtD
Loperamide—Dyspepsia—Stavudine—acquired immunodeficiency syndrome	0.000411	0.00259	CcSEcCtD
Loperamide—Loss of consciousness—Indinavir—acquired immunodeficiency syndrome	0.000407	0.00256	CcSEcCtD
Loperamide—CALM2—lung—acquired immunodeficiency syndrome	0.000406	0.00458	CbGeAlD
Loperamide—Anaphylactic shock—Zidovudine—acquired immunodeficiency syndrome	0.000406	0.00255	CcSEcCtD
Loperamide—Gastrointestinal disorder—Nelfinavir—acquired immunodeficiency syndrome	0.000405	0.00254	CcSEcCtD
Loperamide—Erythema multiforme—Saquinavir—acquired immunodeficiency syndrome	0.000404	0.00254	CcSEcCtD
Loperamide—CALM1—lung—acquired immunodeficiency syndrome	0.000404	0.00456	CbGeAlD
Loperamide—Diarrhoea—Amprenavir—acquired immunodeficiency syndrome	0.000404	0.00254	CcSEcCtD
Loperamide—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000403	0.00254	CcSEcCtD
Loperamide—Fatigue—Stavudine—acquired immunodeficiency syndrome	0.000403	0.00253	CcSEcCtD
Loperamide—Immune system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000401	0.00252	CcSEcCtD
Loperamide—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000399	0.00251	CcSEcCtD
Loperamide—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.000399	0.00251	CcSEcCtD
Loperamide—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000398	0.0025	CcSEcCtD
Loperamide—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.000397	0.0025	CcSEcCtD
Loperamide—Fatigue—Abacavir—acquired immunodeficiency syndrome	0.000397	0.0025	CcSEcCtD
Loperamide—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.000396	0.00249	CcSEcCtD
Loperamide—OPRM1—brain—acquired immunodeficiency syndrome	0.000396	0.00447	CbGeAlD
Loperamide—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.000396	0.00249	CcSEcCtD
Loperamide—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000394	0.00248	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000391	0.00246	CcSEcCtD
Loperamide—Discomfort—Indinavir—acquired immunodeficiency syndrome	0.000389	0.00245	CcSEcCtD
Loperamide—Immune system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000386	0.00243	CcSEcCtD
Loperamide—Asthenia—Didanosine—acquired immunodeficiency syndrome	0.000386	0.00243	CcSEcCtD
Loperamide—Erythema multiforme—Lamivudine—acquired immunodeficiency syndrome	0.000386	0.00243	CcSEcCtD
Loperamide—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.000385	0.00242	CcSEcCtD
Loperamide—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000384	0.00242	CcSEcCtD
Loperamide—Loss of consciousness—Efavirenz—acquired immunodeficiency syndrome	0.000384	0.00242	CcSEcCtD
Loperamide—CYP2C8—blood—acquired immunodeficiency syndrome	0.000384	0.00433	CbGeAlD
Loperamide—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000383	0.00241	CcSEcCtD
Loperamide—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000382	0.00241	CcSEcCtD
Loperamide—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000382	0.0024	CcSEcCtD
Loperamide—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000382	0.0024	CcSEcCtD
Loperamide—Flatulence—Ritonavir—acquired immunodeficiency syndrome	0.000381	0.0024	CcSEcCtD
Loperamide—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000381	0.00239	CcSEcCtD
Loperamide—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000378	0.00238	CcSEcCtD
Loperamide—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000376	0.00237	CcSEcCtD
Loperamide—CALM2—nervous system—acquired immunodeficiency syndrome	0.000376	0.00425	CbGeAlD
Loperamide—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000375	0.00236	CcSEcCtD
Loperamide—CALM1—nervous system—acquired immunodeficiency syndrome	0.000374	0.00423	CbGeAlD
Loperamide—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000372	0.00234	CcSEcCtD
Loperamide—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000372	0.00234	CcSEcCtD
Loperamide—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000372	0.00234	CcSEcCtD
Loperamide—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000371	0.00233	CcSEcCtD
Loperamide—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.00037	0.00233	CcSEcCtD
Loperamide—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.00037	0.00233	CcSEcCtD
Loperamide—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00037	0.00233	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.00037	0.00233	CcSEcCtD
Loperamide—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000369	0.00232	CcSEcCtD
Loperamide—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000368	0.00232	CcSEcCtD
Loperamide—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000368	0.00232	CcSEcCtD
Loperamide—Discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000368	0.00231	CcSEcCtD
Loperamide—Loss of consciousness—Delavirdine—acquired immunodeficiency syndrome	0.000368	0.00231	CcSEcCtD
Loperamide—Flatulence—Saquinavir—acquired immunodeficiency syndrome	0.000367	0.00231	CcSEcCtD
Loperamide—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000367	0.00231	CcSEcCtD
Loperamide—CALM3—brain—acquired immunodeficiency syndrome	0.000366	0.00413	CbGeAlD
Loperamide—CYP2B6—lymphoid tissue—acquired immunodeficiency syndrome	0.000366	0.00413	CbGeAlD
Loperamide—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000366	0.0023	CcSEcCtD
Loperamide—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000364	0.00229	CcSEcCtD
Loperamide—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000364	0.00229	CcSEcCtD
Loperamide—CALM2—central nervous system—acquired immunodeficiency syndrome	0.000362	0.00409	CbGeAlD
Loperamide—CYP2B6—digestive system—acquired immunodeficiency syndrome	0.000362	0.00408	CbGeAlD
Loperamide—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000361	0.00227	CcSEcCtD
Loperamide—CALM1—central nervous system—acquired immunodeficiency syndrome	0.00036	0.00407	CbGeAlD
Loperamide—Dyspepsia—Zidovudine—acquired immunodeficiency syndrome	0.000357	0.00225	CcSEcCtD
Loperamide—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000356	0.00224	CcSEcCtD
Loperamide—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000356	0.00402	CbGeAlD
Loperamide—CALM3—lymph node—acquired immunodeficiency syndrome	0.000354	0.00399	CbGeAlD
Loperamide—Discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000352	0.00221	CcSEcCtD
Loperamide—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000351	0.00221	CcSEcCtD
Loperamide—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000351	0.00221	CcSEcCtD
Loperamide—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.00035	0.0022	CcSEcCtD
Loperamide—Flatulence—Lamivudine—acquired immunodeficiency syndrome	0.00035	0.0022	CcSEcCtD
Loperamide—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.00035	0.0022	CcSEcCtD
Loperamide—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000348	0.00219	CcSEcCtD
Loperamide—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.000347	0.00218	CcSEcCtD
Loperamide—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000347	0.00218	CcSEcCtD
Loperamide—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000347	0.00218	CcSEcCtD
Loperamide—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000345	0.00217	CcSEcCtD
Loperamide—CYP2B6—blood—acquired immunodeficiency syndrome	0.000344	0.00389	CbGeAlD
Loperamide—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000344	0.00217	CcSEcCtD
Loperamide—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000342	0.00215	CcSEcCtD
Loperamide—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000342	0.00215	CcSEcCtD
Loperamide—Loss of consciousness—Ritonavir—acquired immunodeficiency syndrome	0.00034	0.00214	CcSEcCtD
Loperamide—Rash—Didanosine—acquired immunodeficiency syndrome	0.000339	0.00213	CcSEcCtD
Loperamide—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000339	0.00213	CcSEcCtD
Loperamide—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000339	0.00213	CcSEcCtD
Loperamide—Headache—Didanosine—acquired immunodeficiency syndrome	0.000337	0.00212	CcSEcCtD
Loperamide—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000336	0.00211	CcSEcCtD
Loperamide—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000336	0.00211	CcSEcCtD
Loperamide—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000335	0.00211	CcSEcCtD
Loperamide—Dyspepsia—Indinavir—acquired immunodeficiency syndrome	0.000332	0.00209	CcSEcCtD
Loperamide—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000332	0.00209	CcSEcCtD
Loperamide—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000332	0.00209	CcSEcCtD
Loperamide—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000331	0.00209	CcSEcCtD
Loperamide—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000331	0.00208	CcSEcCtD
Loperamide—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.00033	0.00208	CcSEcCtD
Loperamide—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.00033	0.00208	CcSEcCtD
Loperamide—Loss of consciousness—Saquinavir—acquired immunodeficiency syndrome	0.000327	0.00206	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000327	0.00206	CcSEcCtD
Loperamide—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000326	0.00205	CcSEcCtD
Loperamide—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000326	0.00205	CcSEcCtD
Loperamide—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000326	0.00205	CcSEcCtD
Loperamide—Discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000325	0.00205	CcSEcCtD
Loperamide—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000324	0.00204	CcSEcCtD
Loperamide—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000323	0.00203	CcSEcCtD
Loperamide—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000323	0.00203	CcSEcCtD
Loperamide—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000322	0.00203	CcSEcCtD
Loperamide—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000321	0.00202	CcSEcCtD
Loperamide—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000321	0.00202	CcSEcCtD
Loperamide—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.00032	0.00201	CcSEcCtD
Loperamide—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00032	0.00201	CcSEcCtD
Loperamide—CYP2B6—vagina—acquired immunodeficiency syndrome	0.000319	0.0036	CbGeAlD
Loperamide—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000317	0.002	CcSEcCtD
Loperamide—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000315	0.00198	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000315	0.00198	CcSEcCtD
Loperamide—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	0.000314	0.00198	CcSEcCtD
Loperamide—Discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000313	0.00197	CcSEcCtD
Loperamide—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	0.000312	0.00196	CcSEcCtD
Loperamide—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00031	0.00195	CcSEcCtD
Loperamide—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.00031	0.00195	CcSEcCtD
Loperamide—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.00031	0.00195	CcSEcCtD
Loperamide—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000309	0.00194	CcSEcCtD
Loperamide—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000309	0.00194	CcSEcCtD
Loperamide—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000308	0.00194	CcSEcCtD
Loperamide—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000308	0.00194	CcSEcCtD
Loperamide—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000308	0.00194	CcSEcCtD
Loperamide—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000307	0.00193	CcSEcCtD
Loperamide—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000305	0.00192	CcSEcCtD
Loperamide—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000305	0.00192	CcSEcCtD
Loperamide—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000305	0.00192	CcSEcCtD
Loperamide—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000304	0.00191	CcSEcCtD
Loperamide—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000303	0.00191	CcSEcCtD
Loperamide—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000303	0.00191	CcSEcCtD
Loperamide—CYP2B6—lung—acquired immunodeficiency syndrome	0.000302	0.00341	CbGeAlD
Loperamide—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	0.0003	0.00189	CcSEcCtD
Loperamide—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.0003	0.00189	CcSEcCtD
Loperamide—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.0003	0.00189	CcSEcCtD
Loperamide—Discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000299	0.00188	CcSEcCtD
Loperamide—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000298	0.00188	CcSEcCtD
Loperamide—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000298	0.00187	CcSEcCtD
Loperamide—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000298	0.00187	CcSEcCtD
Loperamide—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000297	0.00187	CcSEcCtD
Loperamide—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000296	0.00186	CcSEcCtD
Loperamide—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000295	0.00186	CcSEcCtD
Loperamide—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000295	0.00186	CcSEcCtD
Loperamide—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000295	0.00186	CcSEcCtD
Loperamide—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000295	0.00185	CcSEcCtD
Loperamide—Rash—Stavudine—acquired immunodeficiency syndrome	0.000295	0.00185	CcSEcCtD
Loperamide—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000294	0.00185	CcSEcCtD
Loperamide—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000294	0.00185	CcSEcCtD
Loperamide—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000294	0.00185	CcSEcCtD
Loperamide—Headache—Stavudine—acquired immunodeficiency syndrome	0.000293	0.00184	CcSEcCtD
Loperamide—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000293	0.00184	CcSEcCtD
Loperamide—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000292	0.00184	CcSEcCtD
Loperamide—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000292	0.00184	CcSEcCtD
Loperamide—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000291	0.00183	CcSEcCtD
Loperamide—Rash—Abacavir—acquired immunodeficiency syndrome	0.00029	0.00183	CcSEcCtD
Loperamide—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.00029	0.00182	CcSEcCtD
Loperamide—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.00029	0.00182	CcSEcCtD
Loperamide—Headache—Abacavir—acquired immunodeficiency syndrome	0.000288	0.00181	CcSEcCtD
Loperamide—CALM2—brain—acquired immunodeficiency syndrome	0.000288	0.00324	CbGeAlD
Loperamide—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000287	0.00181	CcSEcCtD
Loperamide—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000287	0.00181	CcSEcCtD
Loperamide—CALM1—brain—acquired immunodeficiency syndrome	0.000286	0.00323	CbGeAlD
Loperamide—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000284	0.00179	CcSEcCtD
Loperamide—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000283	0.00178	CcSEcCtD
Loperamide—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000282	0.00177	CcSEcCtD
Loperamide—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000282	0.00177	CcSEcCtD
Loperamide—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000281	0.00177	CcSEcCtD
Loperamide—CYP2B6—nervous system—acquired immunodeficiency syndrome	0.00028	0.00316	CbGeAlD
Loperamide—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000279	0.00176	CcSEcCtD
Loperamide—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000278	0.00175	CcSEcCtD
Loperamide—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000278	0.00175	CcSEcCtD
Loperamide—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	0.000278	0.00175	CcSEcCtD
Loperamide—CALM2—lymph node—acquired immunodeficiency syndrome	0.000278	0.00314	CbGeAlD
Loperamide—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.000278	0.00175	CcSEcCtD
Loperamide—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000277	0.00175	CcSEcCtD
Loperamide—CALM1—lymph node—acquired immunodeficiency syndrome	0.000277	0.00312	CbGeAlD
Loperamide—ABCB1—retina—acquired immunodeficiency syndrome	0.000275	0.00311	CbGeAlD
Loperamide—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000273	0.00172	CcSEcCtD
Loperamide—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000273	0.00308	CbGeAlD
Loperamide—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.00171	CcSEcCtD
Loperamide—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000272	0.00171	CcSEcCtD
Loperamide—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000271	0.00171	CcSEcCtD
Loperamide—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000271	0.0017	CcSEcCtD
Loperamide—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00027	0.0017	CcSEcCtD
Loperamide—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.00027	0.0017	CcSEcCtD
Loperamide—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.00027	0.0017	CcSEcCtD
Loperamide—CYP2B6—central nervous system—acquired immunodeficiency syndrome	0.000269	0.00304	CbGeAlD
Loperamide—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000269	0.00303	CbGeAlD
Loperamide—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000268	0.00169	CcSEcCtD
Loperamide—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	0.000267	0.00168	CcSEcCtD
Loperamide—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000267	0.00168	CcSEcCtD
Loperamide—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000263	0.00165	CcSEcCtD
Loperamide—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.00165	CcSEcCtD
Loperamide—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.00165	CcSEcCtD
Loperamide—CYP3A4—blood—acquired immunodeficiency syndrome	0.00026	0.00294	CbGeAlD
Loperamide—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.00026	0.00163	CcSEcCtD
Loperamide—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.000258	0.00163	CcSEcCtD
Loperamide—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000258	0.00162	CcSEcCtD
Loperamide—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000258	0.00162	CcSEcCtD
Loperamide—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000258	0.00162	CcSEcCtD
Loperamide—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000256	0.00161	CcSEcCtD
Loperamide—CYP2D6—blood—acquired immunodeficiency syndrome	0.000256	0.00289	CbGeAlD
Loperamide—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.000256	0.00161	CcSEcCtD
Loperamide—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000256	0.00161	CcSEcCtD
Loperamide—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	0.000255	0.00161	CcSEcCtD
Loperamide—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000254	0.0016	CcSEcCtD
Loperamide—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000252	0.00159	CcSEcCtD
Loperamide—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000251	0.00158	CcSEcCtD
Loperamide—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000251	0.00158	CcSEcCtD
Loperamide—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.00157	CcSEcCtD
Loperamide—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.00157	CcSEcCtD
Loperamide—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.00025	0.00157	CcSEcCtD
Loperamide—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.00025	0.00157	CcSEcCtD
Loperamide—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000248	0.00156	CcSEcCtD
Loperamide—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000248	0.00156	CcSEcCtD
Loperamide—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000245	0.00154	CcSEcCtD
Loperamide—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000244	0.00154	CcSEcCtD
Loperamide—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000241	0.00152	CcSEcCtD
Loperamide—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000241	0.00152	CcSEcCtD
Loperamide—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000241	0.00152	CcSEcCtD
Loperamide—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.00024	0.00151	CcSEcCtD
Loperamide—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.00024	0.00151	CcSEcCtD
Loperamide—CYP2C8—brain—acquired immunodeficiency syndrome	0.000238	0.00269	CbGeAlD
Loperamide—Rash—Indinavir—acquired immunodeficiency syndrome	0.000238	0.0015	CcSEcCtD
Loperamide—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.000238	0.0015	CcSEcCtD
Loperamide—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000237	0.00149	CcSEcCtD
Loperamide—Headache—Indinavir—acquired immunodeficiency syndrome	0.000237	0.00149	CcSEcCtD
Loperamide—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000236	0.00148	CcSEcCtD
Loperamide—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000234	0.00147	CcSEcCtD
Loperamide—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000233	0.00146	CcSEcCtD
Loperamide—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.00023	0.00145	CcSEcCtD
Loperamide—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000229	0.00144	CcSEcCtD
Loperamide—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000227	0.00143	CcSEcCtD
Loperamide—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000226	0.00142	CcSEcCtD
Loperamide—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000226	0.00142	CcSEcCtD
Loperamide—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000225	0.00142	CcSEcCtD
Loperamide—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000225	0.00141	CcSEcCtD
Loperamide—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000224	0.00141	CcSEcCtD
Loperamide—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000224	0.00141	CcSEcCtD
Loperamide—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000223	0.00141	CcSEcCtD
Loperamide—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000223	0.0014	CcSEcCtD
Loperamide—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000218	0.00137	CcSEcCtD
Loperamide—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000217	0.00137	CcSEcCtD
Loperamide—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000216	0.00136	CcSEcCtD
Loperamide—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000215	0.00135	CcSEcCtD
Loperamide—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000215	0.00135	CcSEcCtD
Loperamide—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000215	0.00135	CcSEcCtD
Loperamide—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000214	0.00135	CcSEcCtD
Loperamide—CYP2B6—brain—acquired immunodeficiency syndrome	0.000214	0.00241	CbGeAlD
Loperamide—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000214	0.00134	CcSEcCtD
Loperamide—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000212	0.00133	CcSEcCtD
Loperamide—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000211	0.00238	CbGeAlD
Loperamide—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000209	0.00131	CcSEcCtD
Loperamide—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000208	0.00131	CcSEcCtD
Loperamide—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.000208	0.00131	CcSEcCtD
Loperamide—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000208	0.00235	CbGeAlD
Loperamide—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000205	0.00129	CcSEcCtD
Loperamide—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000203	0.00229	CbGeAlD
Loperamide—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000203	0.00128	CcSEcCtD
Loperamide—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.000201	0.00126	CcSEcCtD
Loperamide—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.00126	CcSEcCtD
Loperamide—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.0002	0.00226	CbGeAlD
Loperamide—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000199	0.00125	CcSEcCtD
Loperamide—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000199	0.00125	CcSEcCtD
Loperamide—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.000198	0.00125	CcSEcCtD
Loperamide—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000198	0.00124	CcSEcCtD
Loperamide—ABCB1—lymphoid tissue—acquired immunodeficiency syndrome	0.000196	0.00221	CbGeAlD
Loperamide—ABCB1—digestive system—acquired immunodeficiency syndrome	0.000193	0.00218	CbGeAlD
Loperamide—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.00122	CcSEcCtD
Loperamide—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.000192	0.00121	CcSEcCtD
Loperamide—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.00121	CcSEcCtD
Loperamide—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000191	0.0012	CcSEcCtD
Loperamide—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00019	0.0012	CcSEcCtD
Loperamide—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000187	0.00118	CcSEcCtD
Loperamide—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.00116	CcSEcCtD
Loperamide—ABCB1—blood—acquired immunodeficiency syndrome	0.000184	0.00208	CbGeAlD
Loperamide—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.00115	CcSEcCtD
Loperamide—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.00115	CcSEcCtD
Loperamide—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000182	0.00114	CcSEcCtD
Loperamide—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00018	0.00114	CcSEcCtD
Loperamide—ABCB1—bone marrow—acquired immunodeficiency syndrome	0.000178	0.00201	CbGeAlD
Loperamide—ABCB1—spinal cord—acquired immunodeficiency syndrome	0.000177	0.002	CbGeAlD
Loperamide—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000172	0.00108	CcSEcCtD
Loperamide—ABCB1—vagina—acquired immunodeficiency syndrome	0.000171	0.00193	CbGeAlD
Loperamide—ABCB1—lung—acquired immunodeficiency syndrome	0.000161	0.00182	CbGeAlD
Loperamide—CYP2D6—brain—acquired immunodeficiency syndrome	0.000159	0.00179	CbGeAlD
Loperamide—ABCB1—nervous system—acquired immunodeficiency syndrome	0.000149	0.00169	CbGeAlD
Loperamide—ABCB1—central nervous system—acquired immunodeficiency syndrome	0.000144	0.00162	CbGeAlD
Loperamide—ABCB1—brain—acquired immunodeficiency syndrome	0.000114	0.00129	CbGeAlD
Loperamide—ABCB1—lymph node—acquired immunodeficiency syndrome	0.00011	0.00125	CbGeAlD
Loperamide—CALM1—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	3.18e-05	0.000414	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	3.18e-05	0.000414	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	3.18e-05	0.000413	CbGpPWpGaD
Loperamide—CALM3—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	3.15e-05	0.000409	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	3.13e-05	0.000407	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	3.12e-05	0.000406	CbGpPWpGaD
Loperamide—CALM3—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	3.12e-05	0.000405	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	3.08e-05	0.0004	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—CSF2—acquired immunodeficiency syndrome	3.07e-05	0.000399	CbGpPWpGaD
Loperamide—CALM1—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	3.04e-05	0.000395	CbGpPWpGaD
Loperamide—CALM2—Platelet activation, signaling and aggregation—IL2—acquired immunodeficiency syndrome	3.04e-05	0.000395	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.03e-05	0.000393	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.03e-05	0.000393	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.02e-05	0.000392	CbGpPWpGaD
Loperamide—CALM1—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	3.02e-05	0.000392	CbGpPWpGaD
Loperamide—CALM2—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	3.02e-05	0.000392	CbGpPWpGaD
Loperamide—POMC—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.01e-05	0.00039	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—AGPS—acquired immunodeficiency syndrome	3e-05	0.000389	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.97e-05	0.000386	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—CSF2—acquired immunodeficiency syndrome	2.97e-05	0.000386	CbGpPWpGaD
Loperamide—CALM3—Immune System—MBL2—acquired immunodeficiency syndrome	2.91e-05	0.000378	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	2.89e-05	0.000375	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	2.87e-05	0.000372	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	2.85e-05	0.00037	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	2.82e-05	0.000367	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.82e-05	0.000367	CbGpPWpGaD
Loperamide—CALM2—Immune System—MBL2—acquired immunodeficiency syndrome	2.82e-05	0.000366	CbGpPWpGaD
Loperamide—CALM1—Immune System—MBL2—acquired immunodeficiency syndrome	2.82e-05	0.000366	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.76e-05	0.000359	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	2.68e-05	0.000349	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.67e-05	0.000347	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	2.67e-05	0.000347	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	2.66e-05	0.000345	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.65e-05	0.000345	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.65e-05	0.000345	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	2.65e-05	0.000345	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.64e-05	0.000343	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.64e-05	0.000343	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	2.64e-05	0.000343	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	2.6e-05	0.000338	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	2.6e-05	0.000337	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	2.6e-05	0.000337	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	2.57e-05	0.000334	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	2.57e-05	0.000334	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	2.57e-05	0.000333	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	2.57e-05	0.000333	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.56e-05	0.000332	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.56e-05	0.000332	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	2.56e-05	0.000332	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	2.56e-05	0.000332	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.55e-05	0.000332	CbGpPWpGaD
Loperamide—CALM3—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	2.54e-05	0.000329	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.5e-05	0.000325	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.47e-05	0.000321	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	2.47e-05	0.000321	CbGpPWpGaD
Loperamide—CALM3—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	2.46e-05	0.000319	CbGpPWpGaD
Loperamide—CALM1—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	2.45e-05	0.000319	CbGpPWpGaD
Loperamide—CALM2—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	2.45e-05	0.000319	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.42e-05	0.000314	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	2.42e-05	0.000314	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.39e-05	0.000311	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	2.39e-05	0.00031	CbGpPWpGaD
Loperamide—CALM3—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	2.38e-05	0.00031	CbGpPWpGaD
Loperamide—CALM1—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	2.38e-05	0.000309	CbGpPWpGaD
Loperamide—CALM2—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	2.38e-05	0.000309	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	2.37e-05	0.000308	CbGpPWpGaD
Loperamide—CALM3—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	2.36e-05	0.000307	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.35e-05	0.000305	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.35e-05	0.000305	CbGpPWpGaD
Loperamide—CALM3—DAP12 signaling—IL6—acquired immunodeficiency syndrome	2.35e-05	0.000305	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.31e-05	0.0003	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	2.31e-05	0.0003	CbGpPWpGaD
Loperamide—CALM1—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	2.31e-05	0.000299	CbGpPWpGaD
Loperamide—CALM2—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	2.31e-05	0.000299	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.3e-05	0.000299	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	2.29e-05	0.000298	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	2.29e-05	0.000298	CbGpPWpGaD
Loperamide—CALM3—Immune System—CCR2—acquired immunodeficiency syndrome	2.28e-05	0.000297	CbGpPWpGaD
Loperamide—CALM2—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	2.28e-05	0.000297	CbGpPWpGaD
Loperamide—CALM1—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	2.28e-05	0.000297	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.27e-05	0.000295	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.27e-05	0.000295	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	2.27e-05	0.000295	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	2.27e-05	0.000295	CbGpPWpGaD
Loperamide—CALM1—DAP12 signaling—IL6—acquired immunodeficiency syndrome	2.27e-05	0.000295	CbGpPWpGaD
Loperamide—CALM2—DAP12 signaling—IL6—acquired immunodeficiency syndrome	2.27e-05	0.000295	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.27e-05	0.000295	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	2.24e-05	0.000291	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	2.24e-05	0.000291	CbGpPWpGaD
Loperamide—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.23e-05	0.00029	CbGpPWpGaD
Loperamide—CALM2—Immune System—CCR2—acquired immunodeficiency syndrome	2.21e-05	0.000287	CbGpPWpGaD
Loperamide—CALM1—Immune System—CCR2—acquired immunodeficiency syndrome	2.21e-05	0.000287	CbGpPWpGaD
Loperamide—CALM3—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	2.21e-05	0.000287	CbGpPWpGaD
Loperamide—CALM3—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	2.21e-05	0.000287	CbGpPWpGaD
Loperamide—CALM3—DAP12 interactions—IL6—acquired immunodeficiency syndrome	2.21e-05	0.000287	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	2.19e-05	0.000284	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	2.17e-05	0.000282	CbGpPWpGaD
Loperamide—CALM3—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	2.17e-05	0.000282	CbGpPWpGaD
Loperamide—CALM3—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	2.16e-05	0.000281	CbGpPWpGaD
Loperamide—CALM1—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	2.14e-05	0.000278	CbGpPWpGaD
Loperamide—CALM1—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	2.14e-05	0.000278	CbGpPWpGaD
Loperamide—CALM2—DAP12 interactions—IL6—acquired immunodeficiency syndrome	2.14e-05	0.000278	CbGpPWpGaD
Loperamide—CALM2—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	2.14e-05	0.000278	CbGpPWpGaD
Loperamide—CALM1—DAP12 interactions—IL6—acquired immunodeficiency syndrome	2.14e-05	0.000278	CbGpPWpGaD
Loperamide—CALM2—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	2.14e-05	0.000278	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	2.12e-05	0.000275	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	2.12e-05	0.000275	CbGpPWpGaD
Loperamide—CALM1—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	2.1e-05	0.000273	CbGpPWpGaD
Loperamide—CALM2—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	2.1e-05	0.000273	CbGpPWpGaD
Loperamide—CALM2—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	2.09e-05	0.000271	CbGpPWpGaD
Loperamide—CALM1—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	2.09e-05	0.000271	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.07e-05	0.00027	CbGpPWpGaD
Loperamide—CALM3—Immune System—IFNA1—acquired immunodeficiency syndrome	2.06e-05	0.000267	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.03e-05	0.000264	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.02e-05	0.000262	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—ALB—acquired immunodeficiency syndrome	2e-05	0.00026	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD79A—acquired immunodeficiency syndrome	2e-05	0.000259	CbGpPWpGaD
Loperamide—CALM1—Immune System—IFNA1—acquired immunodeficiency syndrome	1.99e-05	0.000258	CbGpPWpGaD
Loperamide—CALM2—Immune System—IFNA1—acquired immunodeficiency syndrome	1.99e-05	0.000258	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.99e-05	0.000258	CbGpPWpGaD
Loperamide—CALM3—Disease—CXCR4—acquired immunodeficiency syndrome	1.98e-05	0.000258	CbGpPWpGaD
Loperamide—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.96e-05	0.000255	CbGpPWpGaD
Loperamide—CALM3—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.96e-05	0.000254	CbGpPWpGaD
Loperamide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	1.95e-05	0.000254	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—ALB—acquired immunodeficiency syndrome	1.93e-05	0.000251	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—ALB—acquired immunodeficiency syndrome	1.93e-05	0.000251	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD79A—acquired immunodeficiency syndrome	1.93e-05	0.000251	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD79A—acquired immunodeficiency syndrome	1.93e-05	0.000251	CbGpPWpGaD
Loperamide—CALM2—Disease—CXCR4—acquired immunodeficiency syndrome	1.92e-05	0.000249	CbGpPWpGaD
Loperamide—CALM1—Disease—CXCR4—acquired immunodeficiency syndrome	1.92e-05	0.000249	CbGpPWpGaD
Loperamide—CALM1—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.89e-05	0.000246	CbGpPWpGaD
Loperamide—CALM2—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	1.89e-05	0.000246	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	1.85e-05	0.00024	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.82e-05	0.000236	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.79e-05	0.000232	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.78e-05	0.000231	CbGpPWpGaD
Loperamide—POMC—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.78e-05	0.000231	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.76e-05	0.000229	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.73e-05	0.000225	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	1.73e-05	0.000225	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.71e-05	0.000222	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.7e-05	0.000221	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	1.7e-05	0.000221	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.68e-05	0.000218	CbGpPWpGaD
Loperamide—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	1.66e-05	0.000215	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.63e-05	0.000212	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD40LG—acquired immunodeficiency syndrome	1.63e-05	0.000211	CbGpPWpGaD
Loperamide—CALM3—Hemostasis—IL2—acquired immunodeficiency syndrome	1.62e-05	0.000211	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.61e-05	0.000209	CbGpPWpGaD
Loperamide—CALM3—Immune System—CSF2—acquired immunodeficiency syndrome	1.61e-05	0.000209	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD8A—acquired immunodeficiency syndrome	1.61e-05	0.000209	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.59e-05	0.000206	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism of lipids and lipoproteins—ALB—acquired immunodeficiency syndrome	1.58e-05	0.000206	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.58e-05	0.000205	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	1.58e-05	0.000205	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD40LG—acquired immunodeficiency syndrome	1.57e-05	0.000205	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD40LG—acquired immunodeficiency syndrome	1.57e-05	0.000205	CbGpPWpGaD
Loperamide—CALM1—Hemostasis—IL2—acquired immunodeficiency syndrome	1.57e-05	0.000204	CbGpPWpGaD
Loperamide—CALM2—Hemostasis—IL2—acquired immunodeficiency syndrome	1.57e-05	0.000204	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.56e-05	0.000202	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	1.56e-05	0.000202	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD8A—acquired immunodeficiency syndrome	1.56e-05	0.000202	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD8A—acquired immunodeficiency syndrome	1.56e-05	0.000202	CbGpPWpGaD
Loperamide—CALM2—Immune System—CSF2—acquired immunodeficiency syndrome	1.56e-05	0.000202	CbGpPWpGaD
Loperamide—CALM1—Immune System—CSF2—acquired immunodeficiency syndrome	1.56e-05	0.000202	CbGpPWpGaD
Loperamide—CALM3—Immune System—HLA-B—acquired immunodeficiency syndrome	1.55e-05	0.000201	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	1.54e-05	0.0002	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.54e-05	0.000199	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—CD4—acquired immunodeficiency syndrome	1.54e-05	0.000199	CbGpPWpGaD
Loperamide—CALM3—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.52e-05	0.000198	CbGpPWpGaD
Loperamide—CALM3—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.5e-05	0.000195	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	1.5e-05	0.000195	CbGpPWpGaD
Loperamide—CALM2—Immune System—HLA-B—acquired immunodeficiency syndrome	1.5e-05	0.000195	CbGpPWpGaD
Loperamide—CALM1—Immune System—HLA-B—acquired immunodeficiency syndrome	1.5e-05	0.000195	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.48e-05	0.000192	CbGpPWpGaD
Loperamide—CALM1—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.47e-05	0.000192	CbGpPWpGaD
Loperamide—CALM2—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	1.47e-05	0.000192	CbGpPWpGaD
Loperamide—CALM2—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.46e-05	0.000189	CbGpPWpGaD
Loperamide—CALM1—Signaling by NGF—IL6—acquired immunodeficiency syndrome	1.46e-05	0.000189	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.43e-05	0.000186	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	1.43e-05	0.000186	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.39e-05	0.00018	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.39e-05	0.00018	CbGpPWpGaD
Loperamide—CALM3—Disease—CCR5—acquired immunodeficiency syndrome	1.36e-05	0.000177	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.34e-05	0.000174	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.34e-05	0.000174	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	1.34e-05	0.000174	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	1.34e-05	0.000174	CbGpPWpGaD
Loperamide—CALM1—Disease—CCR5—acquired immunodeficiency syndrome	1.31e-05	0.000171	CbGpPWpGaD
Loperamide—CALM2—Disease—CCR5—acquired immunodeficiency syndrome	1.31e-05	0.000171	CbGpPWpGaD
Loperamide—ABCB1—Transmembrane transport of small molecules—ALB—acquired immunodeficiency syndrome	1.31e-05	0.00017	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.2e-05	0.000156	CbGpPWpGaD
Loperamide—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.19e-05	0.000155	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.06e-05	0.000137	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.05e-05	0.000137	CbGpPWpGaD
Loperamide—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.05e-05	0.000136	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.04e-05	0.000135	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.000133	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	1.02e-05	0.000133	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.01e-05	0.000131	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	1.01e-05	0.000131	CbGpPWpGaD
Loperamide—CALM3—Immune System—IFNG—acquired immunodeficiency syndrome	9.57e-06	0.000124	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.52e-06	0.000124	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9.31e-06	0.000121	CbGpPWpGaD
Loperamide—CALM2—Immune System—IFNG—acquired immunodeficiency syndrome	9.26e-06	0.00012	CbGpPWpGaD
Loperamide—CALM1—Immune System—IFNG—acquired immunodeficiency syndrome	9.26e-06	0.00012	CbGpPWpGaD
Loperamide—CALM3—Immune System—CD4—acquired immunodeficiency syndrome	9.24e-06	0.00012	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.21e-06	0.00012	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	9.21e-06	0.00012	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9e-06	0.000117	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	9e-06	0.000117	CbGpPWpGaD
Loperamide—CALM1—Immune System—CD4—acquired immunodeficiency syndrome	8.94e-06	0.000116	CbGpPWpGaD
Loperamide—CALM2—Immune System—CD4—acquired immunodeficiency syndrome	8.94e-06	0.000116	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.88e-06	0.000115	CbGpPWpGaD
Loperamide—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.84e-06	0.000115	CbGpPWpGaD
Loperamide—CALM3—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.58e-06	0.000112	CbGpPWpGaD
Loperamide—CALM3—Disease—CD4—acquired immunodeficiency syndrome	8.53e-06	0.000111	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL2—acquired immunodeficiency syndrome	8.51e-06	0.00011	CbGpPWpGaD
Loperamide—CYP2B6—Metabolism—ALB—acquired immunodeficiency syndrome	8.33e-06	0.000108	CbGpPWpGaD
Loperamide—CALM2—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.3e-06	0.000108	CbGpPWpGaD
Loperamide—CALM1—Innate Immune System—IL6—acquired immunodeficiency syndrome	8.3e-06	0.000108	CbGpPWpGaD
Loperamide—CALM2—Disease—CD4—acquired immunodeficiency syndrome	8.26e-06	0.000107	CbGpPWpGaD
Loperamide—CALM1—Disease—CD4—acquired immunodeficiency syndrome	8.26e-06	0.000107	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL2—acquired immunodeficiency syndrome	8.23e-06	0.000107	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL2—acquired immunodeficiency syndrome	8.23e-06	0.000107	CbGpPWpGaD
Loperamide—CALM3—Metabolism—ALB—acquired immunodeficiency syndrome	8.11e-06	0.000105	CbGpPWpGaD
Loperamide—CALM2—Metabolism—ALB—acquired immunodeficiency syndrome	7.85e-06	0.000102	CbGpPWpGaD
Loperamide—CALM1—Metabolism—ALB—acquired immunodeficiency syndrome	7.85e-06	0.000102	CbGpPWpGaD
Loperamide—CYP2C8—Metabolism—ALB—acquired immunodeficiency syndrome	7.05e-06	9.16e-05	CbGpPWpGaD
Loperamide—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	7.05e-06	9.15e-05	CbGpPWpGaD
Loperamide—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.18e-06	8.03e-05	CbGpPWpGaD
Loperamide—ABCB1—Metabolism—ALB—acquired immunodeficiency syndrome	6.15e-06	7.98e-05	CbGpPWpGaD
Loperamide—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	5.79e-06	7.52e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.5e-06	7.14e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.47e-06	7.11e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.32e-06	6.91e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	5.32e-06	6.91e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.29e-06	6.88e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	5.29e-06	6.88e-05	CbGpPWpGaD
Loperamide—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.22e-06	6.78e-05	CbGpPWpGaD
Loperamide—CALM3—Immune System—IL6—acquired immunodeficiency syndrome	5e-06	6.49e-05	CbGpPWpGaD
Loperamide—CALM2—Immune System—IL6—acquired immunodeficiency syndrome	4.84e-06	6.28e-05	CbGpPWpGaD
Loperamide—CALM1—Immune System—IL6—acquired immunodeficiency syndrome	4.84e-06	6.28e-05	CbGpPWpGaD
Loperamide—CALM3—Disease—IL6—acquired immunodeficiency syndrome	4.62e-06	6e-05	CbGpPWpGaD
Loperamide—CALM2—Disease—IL6—acquired immunodeficiency syndrome	4.46e-06	5.8e-05	CbGpPWpGaD
Loperamide—CALM1—Disease—IL6—acquired immunodeficiency syndrome	4.46e-06	5.8e-05	CbGpPWpGaD
Loperamide—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	3.79e-06	4.92e-05	CbGpPWpGaD
Loperamide—CALM3—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.23e-06	4.2e-05	CbGpPWpGaD
Loperamide—CALM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.13e-06	4.06e-05	CbGpPWpGaD
Loperamide—CALM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	3.13e-06	4.06e-05	CbGpPWpGaD
